Mayo Clinic Laboratory and Pathology Research Roundup: Nov. 26

By Kelley Luedke • November 26, 2018

Share this:

The Research Roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

Effect of Inorganic Nitrite vs. Placebo on Exercise Capacity among Patients with Heart Failure with Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial

There are few effective treatments for heart failure with preserved ejection fraction (HFpEF). Short-term administration of inorganic nitrite or nitrate preparations has been shown to enhance nitric oxide signaling, which may improve aerobic capacity in HFpEF. Mayo Clinic researchers conducted a study to determine the effect of four weeks' administration of inhaled, nebulized inorganic nitrite on exercise capacity in HFpEF. Among 105 patients who were randomized, 98 completed the trial. During the nitrite phase, there was no significant difference in mean peak oxygen consumption as compared with the placebo phase. There were no significant between-treatment phase differences in daily activity levels. Worsening heart failure occurred in 3 participants during the nitrite phase and 8 during the placebo phase. Among patients with HFpEF, administration of inhaled inorganic nitrite for 4 weeks, compared with placebo, did not result in significant improvement in exercise capacity. The study was published in JAMA.

Published to PubMed This Week

• • • • • Predicting Treatment Response Based on RNA Expression in Large Datasets
          Clinical Cancer Research
        • Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates
          Blood Cancer Journal
        • MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal
          Blood Cancer Journal
          
        • Genetic Predictors of Response to Specific Drugs in Primary Myelofibrosis
          Blood Cancer Journal
        • Extramedullary Hematopoiesis in the Absence of Myeloproliferative Neoplasm: Mayo Clinic Case Series of 309 Patients
          Blood Cancer Journal
        • Evaluation for Genetic Disorders in the Absence of a Clinical Indication for Testing: Elective Genomic Testing
          Journal of Molecular Diagnostics
        • GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score
          Cancer Epidemiology, Biomarkers & Prevention
          
        • Evaluation of the CosmosID Bioinformatics Platform for Prosthetic Joint-Associated Sonicate Fluid Shotgun Metagenomic Data Analysis
          Journal of Clinical Microbiology
          
        • Hepatic Angiosarcoma: A Multi-institutional, International Experience with 44 Cases
          Annals of Surgical Oncology
        • Extension of the Mutational and Clinical Spectrum of SOX2 Related Disorders: Description of Six New Cases and a Novel Association with Suprasellar Teratoma
          American Journal of Medical Genetics
          
        • Intermediate and Long-Term Outcomes of Fibroadenoma Excision in Adolescent and Young Adult Patients
          Breast Journal
        • Outcomes after the Implementation of Practice Management Guidelines for the Treatment of Cardiovascular Implantable Device Pocket Infections
          Journal of Surgical Research
          
        • Effect of Plasma Exchange on Antifactor Xa Activity of Enoxaparin and Serum Levetiracetam Levels
          American Journal of Health-System Pharmacy
        • Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma
          Blood Advances

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.